Vandalia Health Charleston Area Medical Center, in collaboration with the CAMC Clinical Trials Center, is the first site in the world to be activated for the Bioflow-48 stent study and has enrolled the first three patients globally. This international study evaluates a new, longer Orsiro Mission 48-mm Sirolimus-Eluting Coronary Stent System to treat complex blockages in the heart’s arteries.
The study will enroll 100 participants across up to 35 sites, including up to 15 in the U.S.
CAMC interventional cardiologists performed the first three cases in the world.
“That means that we are very advanced center,” said Dr. Haytham Alkhaimy, CAMC Interventional Cardiologist. “We are proud to provide all the new treatments, technology and devices to our community.”
Doctors want to know if using this stent is better for patients by covering long lesions with a single stent instead of using multiple overlapping stents.
The CAMC Clinical Trials Center study team includes Kaylea Hoffman, Morgan Bush, Brittany Barnes, Wisam Alzoebie and Jordan Campanelli.
CAMC investigators contributing to this study are principal investigator Elie Gharib, MD; Mitchell Rashid, MD; Elise Anderson, DO; Haytham Alkhaimy, MD; Sangeeta Mandapaka, MD; Joseph Choo, MD; and Richard Han, MD.
To learn more about the CAMC Clinical Trials Center, visit camcmedicine.edu/ClinicalTrials.
*CAUTION: Investigational device. Limited by United States law to investigational use.
